Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Afferent Pharmaceuticals
Time To Grow: SK Bioscience Eyes US Vaccine, CGT Acquisitions This Year
SK Bioscience CEO outlines the progress the firm is making in its growth acceleration strategy, which involves aggressive M&As and other investment plans.
Ring Therapeutics Turns To Anelloviruses To Disrupt Gene Therapy Space
Ring Therapeutics is turning to a previously unexplored family of viruses to improve the safety and efficacy of gene therapy. The preclinical science suggests using these anelloviruses as vectors can deliver payloads precisely and without causing a significant immune response. Human trials will need to demonstrate the technology can live up to its disruptive potential.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
EU Crunch Time For Mirikizumab, New COVID-19 Vaccine & Other Drugs
The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back marketing approval for eight new drugs and a coronavirus vaccine.
- Medical Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.